The CDC estimates that most newheroin addicts first became hooked on prescription pain medicationbefore graduating to heroin, which is stronger and cheaper. (Photoby John Moore/Getty Images) 

(Bloomberg) — The threelargest U.S. drug distributors and a major generic-drugmanufacturer have agreed to pay $260 million to settle the firstfederal trial over the companies' role in fueling the U.S. opioidepidemic.

Drug distributors McKesson Corp., Cardinal Health Inc. andAmerisourceBergen Corp., plus drugmaker Teva PharmaceuticalIndustries Ltd., entered into the agreement with two Ohio countiesjust before the start of the trial Monday in Cleveland.

Continue Reading for Free

Register and gain access to:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Litigation
Emerging Risk